Showing 65,701 - 65,720 results of 101,133 for search '(( 5 ((wt decrease) OR (teer decrease)) ) OR ( 5 ((a decrease) OR (mean decrease)) ))', query time: 1.85s Refine Results
  1. 65701

    Data_Sheet_1_Trends in enrollment, retention, and graduation of United States veterinary technicians/nurses schools.docx by Lori R. Kogan (6517547)

    Published 2024
    “…Forty-three percent of participants indicated a decrease in student enrollment in the last 5 years. …”
  2. 65702

    Nanosized Hybrid Oligoamide Foldamers: Aromatic Templates for the Folding of Multiple Aliphatic Units by David Sánchez-García (1608835)

    Published 2009
    “…For example, a 40mer with a sequence (PQ<sub>4</sub>)<sub>8</sub> folds into a rod-like helix spanning over 16 turns with a length of 5.6 nm. …”
  3. 65703

    Nanosized Hybrid Oligoamide Foldamers: Aromatic Templates for the Folding of Multiple Aliphatic Units by David Sánchez-García (1608835)

    Published 2009
    “…For example, a 40mer with a sequence (PQ<sub>4</sub>)<sub>8</sub> folds into a rod-like helix spanning over 16 turns with a length of 5.6 nm. …”
  4. 65704

    Proposal to update the review: Telephone consultation and triage: Effects on health care use and patient satisfaction by Sek Ying Chair (10147357)

    Published 2023
    “…However, there are some similar reviews but with differences in at least one PICO component. A total of five studies were identified during the preliminary search: Two cluster RCTs (#1 ESTEEM study; Richards et al., 2004) and three individual RCTs (Gamst-Jensen et al., 2019; Hui, Kong, & Wong, 2010; Vorster & Stott, 2011), and one time-series study.…”
  5. 65705

    Relationship between 2D whisker geometry and basepoint parameters. by Hayley M. Belli (5066540)

    Published 2018
    “…<p>(A) Whisker arc length (S) can be described as a decaying exponential function of θ<sub>bp</sub>, decreasing from caudal to rostral. …”
  6. 65706
  7. 65707
  8. 65708
  9. 65709
  10. 65710

    Randomised Double-Blind Comparison of Placebo and Active Drugs for Effects on Risks Associated with Blood Pressure Variability in the Systolic Hypertension in Europe Trial by Azusa Hara (511291)

    Published 2014
    “…</p><p>Findings</p><p>At 2 years, mean between-group differences were 10.5 mm Hg (p<0.0001) for SBP, 0.29 units (p = 0.20) for VIM, and 0.07 mm Hg (p = 0.47) for WVV. …”
  11. 65711

    Corticothalamic inputs from S1 are necessary for the role of POm in perceptual sensory discrimination. by Jia Qi (400499)

    Published 2022
    “…Right, representative images showing the expression of hM4D(Gi)-mCherry in POm (A, C, and E) and eNpHR3.0-eYFP in Sp5i (A), M1/M2 (C), and S1 (E). …”
  12. 65712

    FcRn is responsible for pH/antibody-mediated enhanced transcytosis of HIV-1. by Sandeep Gupta (79684)

    Published 2013
    “…<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003776#s2" target="_blank">Results</a> represent mean+SE of three independent experiments; <i>p</i> = 0.032 comparing wild type and knockdown cells using 2F5 at pH 6.0 (repeated-measures ANCOVA). …”
  13. 65713

    ORC2 knockdown enhances PV replication. by Marsha DeSmet (2513767)

    Published 2016
    “…Values are expressed as mean +/- SEM. * p-value ≤ 0.05. ORC2 shRNA decreased ORC2 protein expression in C33A cells. …”
  14. 65714

    ID2 expression is inversely correlated to miR-9 and miR-103. by Daniela Annibali (148125)

    Published 2012
    “…<p>Ectopic expression of miR-9 and miR-103 decreases ID2. (<b>A</b>) Immunoblotting of ID2 in SK-N-BE (upper panel) and SH-SY5Y (lower panel) cells treated with RA for 3, 6 and 10 days. …”
  15. 65715

    Chronic CSE treatment induced HIF1α accumulation via enhanced lactate production. by Wenyue Sun (134001)

    Published 2011
    “…<p>A. HIF1α levels in OKF6 cells were determined after 4 h of culture in glucose-free Krebs buffer containing 3 or 5 mmol/L lactate. …”
  16. 65716

    Age-related reduction of Na, K-ATPase immunoreactivity in the stria vascularis. by Xinping Hao (570986)

    Published 2014
    “…<p>Sox10 (green) and Na, K-ATPase (31B) immunoreactivity (red) in the StV of a young adult (A–C) and an aged (D–F) mouse. …”
  17. 65717

    Table1_Placental treatment with insulin-like growth factor 1 via nanoparticle differentially impacts vascular remodeling factors in guinea pig sub-placenta/decidua.DOCX by Baylea N. Davenport (14324355)

    Published 2023
    “…Additionally, there are no effective in utero treatment options for FGR. We have developed a nanoparticle to deliver human insulin-like 1 growth factor (hIGF-1) in a trophoblast-specific manner which results in increased expression of hIGF-1. …”
  18. 65718

    Baseline characteristics for pneumonia. by Mathias Aagaard Christensen (19139443)

    Published 2024
    “…</p><p>Results</p><p>Models were generated for atrial fibrillation, venous thromboembolism and pneumonia as genetics only, clinical features only and a combined model. For venous thromboembolism, the ROC-AUCs were 60.1% [59.6%-60.4%], 63.4% [63.2%-63.4%] and 66.6% [66.2%-66.9%] for the linear models and 51.5% [49.4%-53.4%], 63.2% [61.2%-65.0%] and 62.6% [60.7%-64.5%] for the deep learning SNP, clinical and combined models, respectively. …”
  19. 65719

    Complexes with Redox-Active Ligands: Synthesis, Structure, and Electrochemical and Photophysical Behavior of the Ru(II) Complex with TTF-Annulated Phenanthroline by Lawrence K. Keniley (1936060)

    Published 2013
    “…Ru­(II) complexes with chelating ligands, 4′,5′-ethylene­dithio­tetra­thiafulvenyl­[4,5-<i>f</i>]­[1,10]­phenan­throline (<b>L1</b>), 1,3-dithiole-2-thiono­[4,5-<i>f</i>]­[1,10]­phenanthroline (<b>L2</b>), and 1,3-dithiole-2-ono­[4,5-<i>f</i>]­[1,10]­phenanthroline (<b>L3</b>), have been prepared and their structural, electrochemical, and photophysical properties investigated. …”
  20. 65720

    Expression of CD74, CNTF and bFGF after treatment with EPO or EPO-peptide. by Stephanie Busch (417837)

    Published 2014
    “…<p>Four week old heterozygous or homozygous male PKD rats (each n = 5) were treated with 0.5 ml/kg body weight DynEpo three times or EPO-like peptide five days a week intraperitoneally for four weeks. …”